Nivolumab-docetaxel shows response in mCRPC

Key clinical point: Nivolumab plus docetaxel shows good response in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

Major finding: The confirmed overall response rate was 40%. The median time to objective response was 2 months, and the median response duration was 7 months. The confirmed prostate-specific antigen (PSA) 50-response rate (50% or higher decline in PSA) was 46.9%.

Study details: A phase 2, nonrandomized CheckMate 9KD trial of 84 patients with chemotherapy-naive mCRPC who received androgen deprivation therapy and ≤2 prior novel hormonal therapies and were treated with nivolumab and docetaxel with prednisone followed by nivolumab maintenance for ≤2 years.

,

Disclosures: This work was supported by Bristol Myers Squibb (BMS). The authors reported receiving consulting/advisory/speaker fees, travel accommodations, expenses, honoraria, and research funding from various sources. Some authors were employed by/owned stocks in BMS.

Source: Fizazi K et al. Eur J Cancer. 2021 Nov 18. doi: 10.1016/j.ejca.2021.09.043.